Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 106 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CBD Day 3 Clear all
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

NCT06692933
View directory record Official record
Conditions
Interaction
Interventions
Cannabidiol in the form of hemp, Clopidogrel
Drug
Lead sponsor
Washington State University
Other
Eligibility
21 Years to 64 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 15, 2026, 10:00 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Augmenting Effects of L-DOPS With Carbidopa and Entacapone

NCT00547911
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Autonomic Nervous System Diseases
Interventions
Droxidopa, Carbidopa, Entacapone
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Sep 15, 2026, 10:00 PM EDT
No Longer Available No phase listed Expanded access

Treatment of Drug Resistant Epilepsy

NCT02461706
View directory record Official record
Conditions
Epilepsy
Interventions
cannabidiol, Blood Test
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
2 Years to 16 Years
U.S. locations
2
States / cities
Gainesville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 15, 2026, 10:00 PM EDT
Suspended Phase 2 Interventional

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

NCT06538389
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Breast Adenocarcinoma, Breast Ductal Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma, Progesterone Receptor-Positive Breast Carcinoma
Interventions
Biospecimen Collection, BRC-001, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 15, 2026, 10:00 PM EDT
Withdrawn Phase 4 Interventional

Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation

NCT02346630
View directory record Official record
Conditions
Stroke
Interventions
Placebo, Levodopa / Carbidopa, Armeo
Drug · Device
Lead sponsor
Ross D. Zafonte, MD
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 26, 2021 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 2 Interventional Results available

Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine

NCT04192370
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Cannabidiol 600mg
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 1 Interventional

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

NCT02071888
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM, T-cell NHL
Interventions
CB-839, CB-839 and low dose dexamethasone, CB-839, pomalidomide, and low dose dexamethasone
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Scottsdale, Arizona • Denver, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

NCT03000569
View directory record Official record
Conditions
Parkinson Disease
Interventions
SAGE-217, Levodopa, Antiparkinsonian Agent(s)
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Panorama City, California • Jacksonville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 15, 2026, 10:00 PM EDT
Active, not recruiting Early Phase 1 Interventional

Role of CBD in Regulating Meal Time Anxiety in Anorexia Nervosa

NCT04878627
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 2 Interventional

Life's End Benefits of cannaBidiol and tetrahYdrocannabinol

NCT05644262
View directory record Official record
Conditions
Agitation, Dementia
Interventions
T2:C100, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Miami, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 15, 2026, 10:00 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Interactions of Cannabidiol (CBD) With Morphine

NCT05143424
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Morphine Sulfate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia

NCT00789672
View directory record Official record
Conditions
Amblyopia
Interventions
levodopa/carbidopa, patching
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
8 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma

NCT02633007
View directory record Official record
Conditions
Asthma
Interventions
CVT-301 (levodopa inhalation powder), Carbidopa, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Daytona Beach, Florida • North Dartmouth, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm

NCT06219915
View directory record Official record
Conditions
Parkinsonian Signs in Older Persons
Interventions
Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg, Placebo 1, Placebo 2
Drug
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus

NCT05490511
View directory record Official record
Conditions
CBD, Transplant Complication, Kidney Disease, Chronic
Interventions
Tacrolimus single dose, Epidiolex single dose, Epidiolex steady-state and tacrolimus single dose
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Co-Administered CHI-554 and Alcohol

NCT05317507
View directory record Official record
Conditions
Healthy Adults
Interventions
CBD oil, Placebo
Drug
Lead sponsor
Auburn University
Other
Eligibility
21 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 15, 2026, 10:00 PM EDT
Not yet recruiting Phase 3 Interventional

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

NCT07148206
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 1 Interventional

PF 06412562 in Subjects With Advanced Stage Parkinson's Disease

NCT03665454
View directory record Official record
Conditions
Parkinson Disease
Interventions
PF-06412562, Standard of Care Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 15, 2026, 10:00 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Sep 15, 2026, 10:00 PM EDT
Terminated Phase 4 Interventional Results available

L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults

NCT03761030
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Depression
Interventions
L-DOPA, Placebo Oral Tablet
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 15, 2026, 10:00 PM EDT
Not listed Phase 2 Interventional

Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease

NCT02812147
View directory record Official record
Conditions
Parkinson Disease
Interventions
L-DOPS, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
30 Years to 83 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 15, 2026, 10:00 PM EDT
Terminated Phase 4 Interventional Results available

Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing

NCT04650217
View directory record Official record
Conditions
Depressive Disorder
Interventions
Carbidopa/levodopa, Placebo, Exercise training, Control
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 15, 2026, 10:00 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones

NCT04387617
View directory record Official record
Conditions
Urinary Stone
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Sep 15, 2026, 10:00 PM EDT
No Longer Available No phase listed Expanded access

Cannabidiol for Pediatric Epilepsy (Compassionate Use)

NCT02556008
View directory record Official record
Conditions
Refractory Childhood Epilepsy
Interventions
cannabidiol (CBD)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Year to 17 Years
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 15, 2026, 10:00 PM EDT